A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

被引：2
|
作者：
Chen, Jiaying
Ji, Qinghai
Cao, Junning
Ji, Dongmei
Bai, Chunmei
Lin, Yansong
Pan, Bin
Sun, Guofang
Li, Jing
Qi, Chuan
Hua, Ye
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Phase Unit, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Hutchis MediPharma Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
    Sherman, S. I.
    Jarzab, B.
    Cabanillas, M. E.
    Licitra, L. F.
    Pacini, F.
    Martins, R.
    Robinson, B.
    Ball, D.
    McCaffrey, J.
    Shah, M. H.
    Bodenner, D.
    Allison, R.
    Newbold, K.
    Elisei, R.
    O'Brien, J. P.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Trigo Perez, Jose Manuel
    Aller, Javier
    Luis Manzano, Jose
    Garcia Adrian, Silvia
    Zafon, Carles
    Reig, Oscar
    Bohn, Uriel
    Cillan, Elena
    Duran, Manuel
    Gonzalez Astorga, Beatriz
    Lopez, Ana
    Javier, Medina
    Porras, Ignacio
    Reina, Juan J.
    Palacios, Nuria
    Grande, Enrique
    Grau, Juan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Manuel Trigo, Jose
    Aller, Javier
    Luis Manzano, Jose
    Garcia Adrin, Silvia
    Zafon Llopis, Carles
    Reig, Oscar
    Bohn, Uriel
    Ramon y Cajal, Teresa
    Duran-Poveda, Manuel
    Gonzalez Astorga, Beatriz
    Lopez-Alfonso, Ana
    Medina Martinez, Javier
    Porras, Ignacio
    Jose Reina, Juan
    Palacios, Nuria
    Grande, Enrique
    Cillan, Elena
    Matos, Ignacio
    Jose Grau, Juan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (04) : 309 - 317
  • [4] A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas Wilmot
    McCaffrey, Judith C.
    Newbold, Kate
    Allison, Roger
    Martins, Renato
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn A.
    Funahashi, Yasuhiro
    Sellecchia, Rita
    Andresen, Corina
    O'Brien, James P.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC)
    Cabanillas, M. E.
    Kurzrock, R.
    Sherman, S. I.
    Tsimberidou, A. M.
    Waguespack, S.
    Naing, A.
    Busaidy, N.
    Gagel, R.
    Wright, J. J.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [7] Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC)
    Sehgal, Kartik
    Shi, Ruichao
    Pappa, Theodora
    Min, Judy K.
    Oakley, Liam B.
    ONeill, Anne
    Dennis, Michael J.
    Deshpande, Hari Anant
    Haddad, Robert I.
    Lorch, Jochen H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Advanced Radioiodine-refractory differentiated Thyroid Cancer
    Spitzweg, Christine
    Auernhammer, Christoph J.
    Geisler, Julia
    Boeck, Stefan
    Heinemann, Volker
    Bartenstein, Peter
    Goeke, Burkhard
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (03) : 168 - 171
  • [9] A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting
    Brose, Marcia S.
    Shenoy, Sangeeta
    Bhat, Nikhil
    Harlacker, Anne K.
    Yurtal, Raven K.
    Posey, Zakkiyya A.
    Torrente, Dena M.
    Grande, Carolyn
    Squillante, Christian Michael
    Troxel, Andrea
    Yarchoan, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Phase II trial of sunitinib in medullary thyroid cancer (MTC)
    De Souza, J. A.
    Busaidy, N.
    Zimrin, A.
    Seiwert, T. Y.
    Villaflor, V. M.
    Poluru, K. B.
    Reddy, P. L.
    Nam, J.
    Vokes, E. E.
    Cohen, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345